首页> 美国卫生研究院文献>Blood Cancer Journal >Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment

【2h】

Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment

机译：依达拉西布改善CD37抗体BI 836826对化学抗性/复发型CLL细胞的细胞毒性：联合治疗的基本原理

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

期刊名称 Blood Cancer Journal
作者
S Betrian; L Ysebaert; K H Heider; J P Delord; J J Fournié; A Quillet-Mary;
展开▼
作者单位

展开▼
年(卷),期 2016(6),11
年度 2016
页码 e496
总页数 4
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment [J] . S Betrian, L Ysebaert, K H Heider, Blood cancer journal. . 2016,第11期

机译：依达拉西布改善CD37抗体BI 836826对化学抗性/复发性CLL细胞的细胞毒性：联合治疗的基本原理
2. Cytotoxicity of the CD37 antibody BI 836826 against chronic lymphocytic leukaemia cells in combination with chemotherapeutic agents or PI3K inhibitors [J] . Krause Guenter, Baki Imaan, Kerwien Susan, British Journal of Haematology . 2016,第5期

机译：CD37抗体BI 836826与化学治疗剂或PI3K抑制剂联合对慢性淋巴细胞性白血病细胞的细胞毒性
3. Evaluation of the cytotoxic effect of selinexor in combination with chemotherapy or idelalisib toward primary CLL cells [J] . Vitale Candida, Todaro Maria, Griggio Valentina, Leukemia and lymphoma . 2020,第S1期

机译：与化疗或伊尔替尼替氏菌与初级CLL细胞组合的细胞毒性作用评价
4. Synergistic Cytotoxicity Effect by Combination Treatment of Polyketide Derivatives from Annona muricata Linn Leaves and Doxorubicin as Potential Anticancer Material on Raji Cell Line [C] . A N Artanti, O P Astirin, A Prayito International Conference on Advanced Materials for Better Future . 2018

机译：通过从Annona Muricata Linn叶片和多柔比星的聚酮衍生物组合治疗的协同细胞毒性效应作为Raji细胞系的潜在抗癌材料
5. T-Cell Checkpoints, and the PD-1/L1 Pathway in Particular, are a Mode of Resistance to DNA Vaccination and Rational Combination Therapies Improve Vaccine Efficacy for the Treatment of Prostate Cancer. [D] . Rekoske, Brian. 2017

机译：T细胞检查点以及PD-1 / L1途径尤其是对DNA疫苗产生抗药性的一种方式，合理的联合疗法可提高疫苗治疗前列腺癌的功效。
6. Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy [O] . Martin F. M. de Rooij, Annemieke Kuil, Arnon P. Kater, -1

机译：依鲁替尼和依达拉西布协同靶向MCL和CLL中BCR控制的粘附：联合治疗的基本原理
7. Correction to: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B cell non-Hodgkin lymphoma [O] . Frank Kroschinsky, Jan Moritz Middeke, Martin Janz, 2020

机译：对复发或难治性B细胞非霍奇金淋巴瘤的患者中BI 836826（CD37抗体）的校正校正DOSE升级研究

Idelalisib improves CD37 antibody BI 836826 cytotoxicity against chemo-resistant /relapse-initiating CLL cells: a rationale for combination treatment

著录项

相似文献

相关主题

期刊订阅